Reply to: "Comment on "Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker exploration"".
Journal
Journal of hepatology
Journal Volume
84
Journal Issue
3
Start Page
e113
End Page
e115
ISSN
1600-0641
Date Issued
2026-03
Author(s)
Type
letter